TriangleBiospecimen Collection (NCT07061951)
Biospecimen Collection trial for Recurrent Chronic Lymphocytic Leukemia (NCT07061951). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory CLL or SLL who currently need treatment. At least two previous therapies must include both a BTK inhibitor and a BCL-2 inhibitor.
The idea: take mirdametinib twice daily throughout each twenty-eight-day cycle. It blocks MEK, an enzyme in a cell-growth signaling pathway. Researchers measure cancer responses and side effects. Tests include marrow biopsies, blood draws, CT scans and heart ultrasound. Treatment continues unless cancer progresses or toxicity becomes unacceptable.
This phase 2 study plans 20 patients. Jennifer Brown leads nine recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.